Incompressible viscous flow near the leading edge of a flat plate admitting slip

The shear stress at the leading edge, calculated on basis of the Navier-Stokes equations and the no-slip boundary condition, approaches infinity. However, taking into account the mean free path of the molecules, which implies admitting a certain slip, the shear stress becomes inversely proportional to the square root of the Knudsen number κ if κ→0. κ is defined as the ratio between the mean free path and the viscous length. The new boundary condition modifies the shear stress only within the Knudsen region of which the size is of the order of 3 to 4 times the mean free path.

Generating and absorbing boundary conditions for combined wave-current simulations

The CFD simulation tool ComFLOW is extended to investigate the characteristics of wave motions in the presence of steady uniform currents. Initially, the inflow boundary is the superposition of waves and current. Effect of the latter on the former is resolved by solving Navier-Stokes equations within the domain as a next step. A Generating and Absorbing Boundary Condition (GABC) with currents is introduced that allows the simulation of a combined wave-current environment in truncated domain. This GABC is characterized by a rational function approximation of dispersion relation, based on Sommerfeld condition and irrotational wave model. The artificial boundaries where GABC with current is applied are transparent to incoming and outgoing waves and currents simultaneously. The absorption properties of the GABC for various waves and currents are analysed. The temporal and spatial differences of free surface elevation between the small domain and large domain turn out to be small, i.e. the GABC prevents the reflection from the boundaries well. The large domain here is arranged in such a way that the reflected waves and currents will not reach the outflow boundary of the small domain within the simulation time. The behaviour of GABC in 3D domain is also investigated, where waves and currents are traveling under an angle of incidence colinearly

Triplet Exciton Generation in Bulk-Heterojunction Solar Cells based on Endohedral Fullerenes

Organic bulk-heterojunctions (BHJ) and solar cells containing the trimetallic nitride endohedral fullerene 1-[3-(2-ethyl)hexoxy carbonyl]propyl-1-phenyl-Lu3N@C80 (Lu3N@C80-PCBEH) show an open circuit voltage (VOC) 0.3 V higher than similar devices with [6,6]-phenyl-C[61]-butyric acid methyl ester (PC61BM). To fully exploit the potential of this acceptor molecule with respect to the power conversion efficiency (PCE) of solar cells, the short circuit current (JSC) should be improved to become competitive with the state of the art solar cells. Here, we address factors influencing the JSC in blends containing the high voltage absorber Lu3N@C80-PCBEH in view of both photogeneration but also transport and extraction of charge carriers. We apply optical, charge carrier extraction, morphology, and spin-sensitive techniques. In blends containing Lu3N@C80-PCBEH, we found 2 times weaker photoluminescence quenching, remainders of interchain excitons, and, most remarkably, triplet excitons formed on the polymer chain, which were absent in the reference P3HT:PC61BM blends. We show that electron back transfer to the triplet state along with the lower exciton dissociation yield due to intramolecular charge transfer in Lu3N@C80-PCBEH are responsible for the reduced photocurrent

Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction

Background: This study was designed to investigate the association of the 894G>T polymorphism in the eNOS gene with risk of acute myocardial infarction (AMI), extent of coronary artery disease (CAD) on coronary angiography, and in-hospital mortality after AMI. Methods: We studied 1602 consecutive patients who were enrolled in the GEMIG study. The control group was comprised by 727 individuals, who were randomly selected from the general adult population. Results: The prevalence of the Asp298 variant of eNOS was not found to be significantly and independently associated with risk of AMI (RR = 1.08, 95%CI = 0.77–1.51, P = 0.663), extent of CAD on angiography (OR = 1.18, 95%CI = 0.63–2.23, P = 0.605) and in-hospital mortality (RR = 1.08, 95%CI = 0.29–4.04, P = 0.908). Conclusion: In contrast to previous reports, homozygosity for the Asp298 variant of the 894G>T polymorphism in the eNOS gene was not found to be associated with risk of AMI, extent of CAD and in-hospital mortality after AM

On the elastic beam-fluid intreaction based on structural mode shapes

The concept of fluid-structure interaction(FSI) has a vast range of practical engineering applications. Since the analytical solution for such a systems is not available, numerical methods are adopted. Two main approaches are monolithic and partitioned methods. Treating the coupled system of fluid and structure simultaneously as in monolithic approach will limit the flexibility, in the other hand this property is maintained by decomposing the physical system into fluid and structure. Using a partitioned approach, the solution is separately advanced in time over each partition. Interaction effects are accounted for by transmission and synchronization of coupled state variables. The strength of the coupling is traditionally maintained by correcting the interaction effects iteratively. Besides convergence’s high computational cost, the physics of the interaction can also jeopardize an iterative procedure. For two-way physically coupled systems the information exchange among two partitions (fluid and structure) is relaxed to avoid numerical instabilities. In this paper, the idea of preserving coupling strength by catching the presence of the structure through an interaction law is studied and formulated. The structural modal representation is utilized to derive the interaction boundary at the fluid-structure interface. Since this approach strongly enforces the information exchange on the fluid-structure interface, the source of instabilities is abolished. As a test case, a 1D Euler-Bernoulli beamlocated at the bottom of a 2D tank is strongly coupled with a fluid above by means of iterative under-relaxed coupling results and also the weak coupling. The results are shown and then discussed

Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation

INTRODUCTION: Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications are unknown. OBJECTIVES: The aim of this study was to investigate the incidence of gallstones on imaging and related complications in unbiased trial data. METHODS: Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care (SoC) or lanreotide for 120 weeks, were used. Magnetic resonance imaging (MRI) was performed at baseline and end of treatment and was assessed for the presence, number, and size of gallstones. For all patients who had gallstones at the end of the trial, we obtained follow-up after the trial. RESULTS: Of 249 patients with data available, 11 patients randomized to lanreotide and four randomized to SoC had gallstones at baseline. During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%). The odds ratio for gallstone formation with lanreotide use was 25.9 (95% confidence interval 3.37–198.8; p  20 stones in 69% of patients) and small (≤ 3 mm in 63% of patients). Of the 19 patients with incident gallstones during lanreotide treatment, 9 experienced gallstone-associated complications, 8 of whom experienced gallstone-associated complications after discontinuation of treatment (median time after discontinuation 2.5 years). In patients with gallstones at baseline and in patients receiving SoC, no complications occurred. CONCLUSIONS: Treatment with a somatostatin analog leads to the formation of multiple, small gallstones that are associated with severe complications, especially after discontinuation of therapy. CLINICAL TRIAL REGISTRY WEBSITE AND TRIAL NUMBER: ClinicalTrials.gov (https://clinicaltrials.gov); NCT01616927. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40268-021-00342-7